Diagnostear Technologies Inc

DiagnosTear Technologies, Inc. is an ophthalmic company, which engages in the developing and commercializing disruptive diagnostic solutions for better management of eye diseases. The company is headquartered in Rehovot, Central(Hamerkaz). The company went IPO on 2024-12-09. The firm develops the TeaRx™ technology, a tear‑fluid analytical platform designed for identifying and monitoring front‑of‑the‑eye diseases. The company focuses on research and development of diagnostic tests, clinical validation activities, regulatory readiness, and establishing production capabilities, supported partly through government‑funded research and development(R&D) programs. The firm operates through a single reportable segment dedicated to tear‑based ophthalmic diagnostic solutions, including test development, production line preparation, commercialization planning, and ongoing enhancement of its technological capabilities.